Sanofi, Regeneron's Dupixent Gets FDA Approval for COPD
WEB1 day ago · Dupixent is a key top-line driver for both Sanofi and Regeneron on strong demand trends. In the first half of 2024, Dupixent generated global product sales of $€6.1 billion, which were recorded ...
Sanofi US News
WEB4 days ago · Sanofi and Regeneron are committed to helping patients in the US who are prescribed Dupixent gain access to the medicine and receive the support they may need with the DUPIXENT MyWay ® program. For more information, please call 1-844-DUPIXENT (1-844-387-4936) or visit www.DUPIXENT.com.
FDA signs off on Regeneron and Sanofi's Dupixent for COPD
WEB3 days ago · Regeneron and Sanofi have announced that the FDA has expanded the label of megablockbuster Dupixent to treat COPD. The approval brings the versatile drug’s count of U.S. indications up to six ...
FDA, after delay, clears Regeneron and Sanofi drug for COPD
WEB4 days ago · European regulators approved Dupixent for COPD in July, but Regeneron and Sanofi have had to wait longer in the U.S., where the FDA requested additional efficacy data from the two trials. Over that time, a potential new competitor has emerged in GSK’s Nucala, which the FDA rejected in 2018 but earlier this month succeeded in a Phase 3 trial.
Dupixent® (dupilumab) Approved in China as the First-ever …
WEB3 days ago · About Regeneron and Sanofi’s COPD Clinical Research Program Regeneron and Sanofi are motivated to transform the treatment paradigm of COPD by examining the role different types of inflammation play in the disease progression through the investigation of two potentially first-in-class biologics, Dupixent and itepekimab.
Blockbuster Dupixent wins FDA approval for COPD - STAT
WEB3 days ago · Regeneron, Sanofi blockbuster Dupixent wins FDA approval for COPD Drug is cleared for 300,000 U.S. patients with a form of the lung disease driven by eosinophils Manage alerts for this article
Sanofi-Regeneron's Dupixent wins FDA's nod for 'smoker's lung'
WEBBy Sriparna Roy (Reuters) -The U.S. Food and Drug Administration has approved Sanofi and Regeneron's blockbuster drug Dupixent for patients with a chronic lung disease, commonly known as "smoker's ...
INVESTORS & MEDIA - Regeneron Pharmaceuticals Inc.
WEBMay 31, 2024 · Regeneron and Sanofi are motivated to transform the treatment paradigm of COPD by examining the role different types of inflammation play in the disease progression through the investigation of two potentially first-in-class biologics, Dupixent and itepekimab.
Regeneron, Sanofi's Dupixent Get FDA Approval For Chronic
WEB3 days ago · Dupixent is awaiting regulatory approvals in several nations across the world, including in Japan, Sanofi noted. Currently, Regeneron's stock is trading at $1,063.05, up 2.22 percent, and Sanofi's ...
US FDA approves Sanofi-Regeneron's Dupixent for 'smoker's …
WEB3 days ago · View comments. (Reuters) -The U.S. Food and Drug Administration has approved Sanofi and Regeneron's blockbuster drug Dupixent for patients with a chronic lung disease, commonly known as "smoker's ...